Fennec Pharmaceuticals Inc (NASDAQ: FENC – Get Rating) – Investment analysts at Capital One Financial increased their FY2023 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, September 20th. Capital One Financial analyst N. Quibria now expects that the company will post earnings of ($ 0.36) per share for the year, up from their previous forecast of ($ 0.37). Capital One Financial has a “Overweight” rating and a $ 11.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($ 0.62) per share.
Several other research firms have also recently issued reports on FENC. Craig Hallum reiterated a “buy” rating and issued a $ 14.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday, August 8th. Wedbush reissued an “outperform” rating and set a $ 11.00 price target on shares of Fennec Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $ 11.50.
Fennec Pharmaceuticals Price Performance
Shares of FENC opened at $ 8.03 on Friday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.47. The stock’s 50 day moving average is $ 6.89 and its two-hundred day moving average is $ 6.18. Fennec Pharmaceuticals has a twelve month low of $ 3.82 and a twelve month high of $ 8.75. The firm has a market capitalization of $ 209.41 million, a PE ratio of -11.99 and a beta of 0.09.
Fennec Pharmaceuticals (NASDAQ: FENC – Get Rating) last announced its earnings results on Friday, August 12th. The company reported ($ 0.19) EPS for the quarter, missing analysts’ consensus estimates of ($ 0.10) by ($ 0.09).
Institutional Investors Weigh In On Fennec Pharmaceuticals
An institutional investor recently raised its position in Fennec Pharmaceuticals stock. DG Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals Inc (NASDAQ: FENC – Get Rating) by 4.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,210,638 shares of the company’s stock after purchasing an additional 51,249 shares during the quarter. Fennec Pharmaceuticals makes up about 1.4% of DG Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. DG Capital Management LLC owned 4.65% of Fennec Pharmaceuticals worth $ 6,780,000 as of its most recent SEC filing. Institutional investors own 43.29% of the company’s stock.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Fennec Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on … and Fennec Pharmaceuticals wasn’t on the list.
While Fennec Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here